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Key messages 
What is already known about this subject? 
• Very few studies have demonstrated the potential role of ultrasound (US) for the prediction 
of clinical arthritis in individuals at-risk of rheumatoid arthritis (RA);  
• These studies have focused on subclinical synovitis, rather than the role of bone erosions; 
What does this study add? 
• Our study provides new insights into the prevalence, pattern, and relationship with subclinical 
synovitis of US detected bone erosions in anti-cyclic citrullinated positive (CCP+) individuals 
without clinical synovitis; 
• The detection of US bone erosions in the classic sites for RA damage, especially in the fifth 
metatarsophalangeal (MTP5) joints, significantly improves prediction of inflammatory 
arthritis in CCP+ at-risk individuals; 
How might this impact on clinical practice? 
• In CCP+ at-risk individuals without clinical synovitis, the detection of bone erosions on US, 
especially at the MTP5 joints, may improve risk-stratification and therefore inform 
management of these individuals.  
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Abstract  
Objectives 
To investigate, in anti-cyclic citrullinated peptide antibody positive (CCP+) at-risk individuals without 
clinical synovitis, the prevalence and distribution of ultrasound (US) bone erosions (BE), their 
correlation with subclinical synovitis, and their association with the development of inflammatory 
arthritis (IA). 
Methods 
Baseline US scans of 419 CCP+ at-risk individuals were analysed. BE were evaluated in the classical 
sites for rheumatoid arthritis damage: the second and fifth metacarpophalangeal (MCP2 and MCP5) 
joints, and the fifth metatarsophalangeal (MTP5) joints. US synovitis was defined as synovial 
ｴ┞ヮWヴデヴﾗヮｴ┞ ふ“Hぶ дヲ ﾗヴ “H дヱ Щ ヮﾗ┘Wヴ DﾗヮヮﾉWヴ ゲｷｪﾐ;ﾉ дヱく S┌HﾃWIデゲ ┘ｷデｴ дヱ aﾗﾉﾉﾗw-up visit were included 
in the progression analysis (n=400).  
Results  
BE ┘WヴW aﾗ┌ﾐS ｷﾐ дヱ ﾃﾗｷﾐデ ｷﾐ ヴヱっヴヱΓ ゲ┌HﾃWIデゲ ふΓくΒХぶ, and in 55/2514 joints (2.2%). The prevalence of 
BE was significantly higher in the MTP5 joints than in the MCP joints (p<0.01). A significant correlation 
between BE and US synovitis in the MTP5 joints was detected ふCヴ;ﾏWヴげゲ VЭヰくンΑが ヮаヰくヰヱぶ. The odds 
ratio (OR) for the development of IA (ever) was highest for the following: BE in >1 joint 10.6 (95%CI 
1.9-60.4, p<0.01) and BE and synoviデｷゲ ｷﾐ дヱ MTP5 joint 5.1 (95%CI 1.4-18.9, p=0.02). In high-titre CCP+ 
individuals, with positive rheumatoid factor and BE in дヱ joint, the OR increased to 16.9 (2.1-132.8, 
p<0.01).  
Conclusions 
In CCP+ at-risk individuals, BE in the feet appear to precede the onset of clinical synovitis. BE in >1 
joint, and BE in combination with US synovitis in the MTP5 joints, are the most predictive for the 
development of clinical arthritis.  
 
 
 
 
 
 
4 
 
Introduction 
Bone erosions are cardinal features of rheumatoid arthritis (RA) and their central role in the 
pathogenesis, diagnosis and prognosis of the disease is widely recognised (1,2). They have traditionally 
been considered as late-stage lesions, developing as a consequence of persistent synovitis. However, 
several studies have showed that bone erosions might occur very early in the course of RA (3). 
Moreover, recent studies have demonstrated that bone loss can occur in the pre-clinical phases of the 
disease (4), and long before the onset of clinical synovitis in some subjects with positive anti cyclic-
citrullinated peptide (CCP+) antibodies (Ab) (5).  
Bone erosions represent joint damage in RA, and as such are important biomarkers for disease 
severity. Indeed, their presence has been associated with poor functional outcome and irreversible 
loss of function (6,7). Since most RA patients develop bone erosions within 12-24 months of disease 
onset (some patients a few weeks after disease onset), their early detection and recognition is of 
critical importance for guiding management (8,9), with potential implications for treatment 
approaches aimed at preventing further joint damage and disability (10).  
Conventional radiography remains the imaging tool most commonly used for the detection of bone 
erosions in RA (11). However, in recent years, the use of musculoskeletal ultrasound (US) in the 
assessment of RA patients has increased significantly (12). US has been shown to be more sensitive 
than conventional radiography for the detection of bone erosions, especially in the early phase of the 
disease (13,14).  
While the central role of bone erosions in patients with RA is widely recognized, their prevalence, 
pattern, and relationship with subclinical synovitis in individuals at-risk of RA (e.g. anti-CCP+ with 
musculoskeletal symptoms but without clinical arthritis) is not well understood. To the best of our 
knowledge, among the few studies that have evaluated the role of US in individuals at-risk of RA (15-
19), only one has explored the predictive role of bone erosions for the development of clinical arthritis 
(17). Nam et al. showed that the presence of US detected bone erosions, in addition to grey scale and 
power Doppler (PD) synovitis, could predict progression to IA in 136 CCP+ individuals with 
musculoskeletal symptoms but without clinical arthritis, raising implications for the risk stratification 
of individuals at-risk of RA (17).  
The detection of reliable biomarkers, which help to identify individuals at-risk for future arthritis, is a 
critical prerequisite for RA prevention trials. It is also important that such biomarkers are readily 
available to rheumatologists who are now routinely being referred at-risk individuals in clinical 
practice (20). As such, a focused US examination, which enabled risk stratification in the clinic setting, 
would be invaluable for managing these patients.  
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We hypothesised that a targeted US examination, evaluating the areas that have been reported as 
most specific for the identification of US bone erosions in RA (21), could be used for risk prediction in 
individuals at-risk of RA. Based on these considerations, the objectives of this study were two-fold: 
• To determine, in CCP+ at-risk individuals without clinical synovitis (CCP+ at-risk), the 
prevalence and distribution of US bone erosions, and their correlation with subclinical 
synovitis, in the classical sites for RA damage: the second and fifth metacarpophalangeal 
(MCP2 and MCP5) joints, and the fifth metatarsophalangeal (MTP5) joints; 
• To study the association between US detected bone erosions and the development of clinical 
arthritis.  
Materials and methods 
The baseline US scans (from June 2008 to December 2019) of CCP+ at-risk individuals, with 
musculoskeletal symptoms but without clinical synovitis, aヴﾗﾏ さTｴW CCP “デ┌S┞ぎ CﾗﾗヴSｷﾐ;デWS 
Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-IﾉｷﾐｷI;ﾉ “デ;ｪWいざ, were analysed. 
Full details of the Leeds CCP study have been published previously (22). Briefly, in this national study, 
individuals with new musculoskeletal joint symptoms presenting to their primary care physician (or 
other health professional) are tested for anti-CCP Ab. Those who test positive for anti-CCP Ab are 
invited to a dedicated research clinic in Leeds, United Kingdom, as part of a prospective observational 
study.  
The US evaluations were carried out by rheumatologists experienced in sonography and 
sonographersが HﾉｷﾐSWS デﾗ デｴW ｷﾐSｷ┗ｷS┌;ﾉゲげ IﾉｷﾐｷI;ﾉ S;デ;く The US and clinical examinations were 
conducted by different physicians. All the US operators had a training session on the scanning 
protocol. The US scans were initially carried out using a Philips (ATL HDI 5000) machine working with 
5に12 MHz and 8に15 MHz transducers. A small number of US scans were then performed using a 
General Electric (GE) S7 machine, employing a 6に15 MHz transducer. Due to the change in the US 
machine during the course of the study, sensitivity analyses between the first two US machines (Philips 
ATL HDI 5000 and GES7) were performed (17). Subsequently (from 2014) a GE Logiq E9 machine, 
employing a 6に15 MHz transducer, was used. PD was set as follows: pulse repetition frequency (PRF) 
700-1000 Hz, Doppler frequency 6 MHz for the Philips (ATL HDI 5000), 10 MHz for the GE S7 and GE 
Logic E9.  
The presence of bone erosions and synovitis was explored in the MCP2 joints, MCP5 joints, and MTP5 
joints. These have been reported as the most specific joints for the detection of US bone erosions in 
RA (21). Bone erosions were identified as intra-articular discontinuities of the bone surface that are 
visible in two perpendicular planes, according to the Outcome Measure in Rheumatology (OMERACT) 
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definitions (23). The size of bone erosions (diameter of the cortical break) was evaluated according to 
a semi-quantitative scoring system (from 0 to 3) where 0: no definite erosion, 1: erosions <2 mm, 2: 
erosion 2-4 mm, and 3: erosions > 4 mm (14, 24). The dorsal, lateral and palmar aspects of the joints 
were assessed for the presence of bone erosions. “┞ﾐﾗ┗ｷデｷゲ ┘;ゲ SWaｷﾐWS ;ゲ ゲ┞ﾐﾗ┗ｷ;ﾉ ｴ┞ヮWヴデヴﾗヮｴ┞ дヲが 
ﾗヴ ゲ┞ﾐﾗ┗ｷ;ﾉ ｴ┞ヮWヴデヴﾗヮｴ┞ дヱ Щ ヮﾗ┘Wヴ DﾗヮヮﾉWヴ ゲｷｪﾐ;ﾉ дヱが ;IIﾗヴSｷﾐｪ デﾗ デｴW OMERACT SWaｷﾐｷデｷﾗﾐゲ ふ25).   
For each individual, the following data were collected: age, sex, smoking exposure, x-rays of the hands 
and feet, second generation anti-CCP (CCP2) Ab titre (BioPlex 2200 CCP2, BioRad, USA), and 
rheumatoid factor (RF) status (positivity/negativity). Anti-CCP2 test positivity threshold was set at 
>2.99 IU/ml, according to manufaIデ┌ヴWヴげゲ I┌デ-offs. Anti-CCP2 titre was considered low or high when it 
┘;ゲ а ﾗヴ д デｴ;ﾐ ン デｷﾏWゲ デｴW ヮﾗゲitivity threshold, respectively, according to the American College of 
Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 criteria (2). Rheumatoid 
a;Iデﾗヴ ヮﾗゲｷデｷ┗ｷデ┞ ┘;ゲ ゲWデ ;デ дヲヰ IUっﾏﾉく MﾗヴWﾗ┗Wヴが aﾗヴ W;Iｴ ｷﾐSｷ┗ｷS┌;ﾉが tenderness on physical 
examination in the small joints of the hands and feet (MCP2, MCP5 and MTP5 joints), was also 
registered. According to the study protocol, the CCP+ at-risk individuals were assessed at baseline, at 
3-monthly intervals for the first year, and then yearly or until they developed IA. The US scans were 
repeated at 6 and 12 months visits and then yearly (unless the individuals developed IA). Anti-CCP Ab, 
RF and X-rays of the hands and feet were performed at baseline and then annually, or when they 
developed IA.   
Only CCP+ at-risk  individuals ┘ｷデｴ дヱ aﾗﾉﾉﾗ┘-up visit were included in the progression analysis (n=400). 
Individuals who withdrew from the study were excluded from this analysis. Progression to IA was 
SWaｷﾐWS ;ゲ デｴW SW┗WﾉﾗヮﾏWﾐデ ﾗa IﾉｷﾐｷI;ﾉ ゲ┞ﾐﾗ┗ｷデｷゲ ふデWﾐSWヴﾐWゲゲ ;ﾐS ゲ┘Wﾉﾉｷﾐｪぶ ｷﾐ дヱ ﾃﾗｷﾐデく RA ┘;ゲ SWaｷﾐWS 
according to the 2010 ACR/EULAR RA classification criteria (2). 
Patient and Public involvement  
The design of the Leeds CCP study including biomarkers measured and data collected has been 
informed by several patient and public involvement (PPI) meetings, hosted by the Leeds Biomedical 
Research Centre PPI group, in which patients and public partners were actively involved.  Within these 
PPI groups, different potential biomarkers were discussed, which could help identify risk factors for 
the development of RA. The PPI group placed significant importance on the use of routinely available 
clinical biomarkers, such as blood tests (i.e., autoAb, inflammatory markers) and imaging exams (i.e., 
musculoskeletal US), in risk stratifying individuals at-risk of RA. PPI members were involved at different 
stages of the study and their preferences and priorities informed the development of the study.   
Ethics approval 
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This study was approved by the NHS Health Research Authority National Research Ethics Service 
Committee Yorkshire & the Humber に Leeds West. 
Statistical analysis  
Results are expressed as mean and standard deviation (SD) for the quantitative variables with a normal 
distribution, as median and inter-quartile range (IQR) for those without a normal distribution 
(Kolmogorov-Smirnov test), and as absolute frequency with corresponding percentage for the 
qualitative variables. The Student t-test was used for comparing quantitative variables with a normal 
distribution, the Mann-Whitney test for those without a normal distribution, and the Chi-Square test 
for the qualitative variables. To test the hypothesis that bone erosion and synovitis coexist in the same 
joint, we performed a Chi Square test evaluating a 2x2 contingency table (presence/absence of 
synovitis and presence/absence of bone erosions). The strength of the relationship between US 
findings was measured using Cヴ;ﾏWヴげゲ Vく M┌ﾉデｷヮﾉW ﾉﾗｪｷゲデｷI ヴWｪヴWゲゲｷﾗﾐ ;ﾐ;ﾉ┞ゲｷゲ ┘;ゲ ┌ゲWS デﾗ SWaｷﾐW 
predictive values of US findings for the development of clinical arthritis (at 1 year, at 3 years and ever). 
All regression analyses were adjusted for age, gender, smoking exposure, anti-CCP2 titre and RF status. 
Significance-based backward stepwise selection of variables was used for the final multivariable 
model. All covariates with a p<0.10 in the univariable models were included in the multivariable 
models. Kaplan-Meier analysis and Log-Rank test were performed to analyse and visualize the IA free 
survival time for the US findings. These analyses were adjusted by the same parameters as the 
regression analysis. Statistical analysis was performed using SPSS (Statistical Package for the Social 
Sciences) software version 24.0 for windows (Chicago, Illinois, USA). The level of significance was set 
at 5%. 
Results 
- Demographic and clinical characteristics of the CCP+ at-risk individuals 
A total of 2514 joints, in 419 CCP+ at-risk individuals, were evaluated. The median follow-up was 497 
days (IQR: 256-1111.5 days). The demographic and clinical characteristics of the CCP+ at-risk 
individuals are reported in Table 1. 
Table 1. Baseline demographic and clinical characteristics of the CCP+ at-
risk individuals 
Age, years (mean±SD) 50.9±13.4 
Sex   
- Female  302 (72.1%) 
- Male  117 (27.9%) 
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Anti-CCP2 Ab   
- High デｷデヴW ふдΓ IU/ml) 290 (69.2%) 
- Low titre (<9 IU/ml) 129 (30.8%) 
Rheumatoid factor positivity ふдヲヰ 
IU/ml) 
160 (38.2%) 
Smoking exposure   
- Never smoker 181(43.2%) 
- Previous smoker 143 (34.1%) 
- Current smoker 95 (22.7%) 
 
Percentages refer to the total number of individuals (n= 419).  
 
- US bone erosions: prevalence, distribution, association with subclinical synovitis, tenderness 
on physical examination and x-rays findings 
BﾗﾐW Wヴﾗゲｷﾗﾐゲ ┘WヴW aﾗ┌ﾐS ｷﾐ дヱ ﾃﾗｷﾐデ ｷﾐ ヴヱ ﾗ┌デ ヴヱΓ ふ9.8%) individuals, and in 55 out of the 2514 (2.2%) 
joints scanned. Bilateral and symmetrical erosions were identified in 11 out of 41 (26.8%) individuals. 
The prevalence of bone erosions was significantly higher in the MTP5 joints than in the MCP2 joints 
and MCP5 joints (p<0.01). In particular, bone erosions were detected in 42 MTP5 joints (31 individuals; 
7.4%), in 10 MCP2 joints (10 individuals; 2.4%), and in 3 MCP5 joints (3 individuals; 0.7%).  
BﾗﾐW Wヴﾗゲｷﾗﾐゲ ｷﾐ дヱ MTP5 joint were found in 12 out of 13 (92.3%) individuals with multiple (>1 joint) 
bone erosions. The distribution and size of the US detected bone erosions are reported in Table 2. 
Table 2. Distribution and size of US bone erosions. 
 MCP2 joints MCP5 joints MTP5 joints Total 
Bone erosions 
10 
(18.2%) 
3 
(5.5%) 
42 
(76.4%) 
55 
Grade 1 
9 
(16.4%) 
3 
(5.5%) 
29 
(52.7%) 
41 
(74.5%) 
Grade 2 0 0 
11 
(20%) 
11 
(20%) 
Grade 3 
1 
(1.8%) 
0 
2 
(3.6%) 
3 
(5.5%) 
Percentage refer to the total number of joints with bone erosions (n=55). 
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A significant correlation between bone erosion and synovitis in the same joint was detected for MTP5 
ﾃﾗｷﾐデゲ ふCヴ;ﾏWヴげゲ VЭヰくンΑが ヮаヰくヰヱぶが ┘ｴWヴW;ゲ ｷデ ┘;ゲ ﾐﾗデ ゲｷｪﾐｷaｷI;ﾐデ for MCP2 ﾃﾗｷﾐデゲ ふCヴ;ﾏWヴげゲ VЭヰくヰヲが 
p=1.0), and for MCP5 ﾃﾗｷﾐデゲ ふCヴ;ﾏWヴげゲ VЭヰくヰヲが ヮЭヰくヴヱぶ, likely due to the low number of bone erosion 
at these levels. US synovitis was detected in 145 (5.8%) joints, in 96 (22.9%) individuals. US synovitis 
was found in 22 out of 55 (40%) joints with bone erosions, in 17 out of 41 (41.5%) individuals. In 
particular, US synovitis was found in 18 out of 42 (42.8%) MTP5 joints, in 2 out of 10 (20%) MCP2 
joints, and in none of 3 MCP5 joints showing bone erosions. Synovitis was found in 13 out of the 41 
(31.7%) joints showing grade 1 bone erosions. No significant difference in the size of bone erosions in 
the joints with concomitant synovitis in comparison with those without synovitis was found (p=0.114). 
On the other hand, US bone erosions were found in 22 out of 145 (15.2%) joints with US synovitis. In 
particular, US bone erosions were detected in 20 out the 55 (36.4%) MTP5 joints, in 2 out of the 66 
(3%) MCP2 joints, and in none of the 24 MCP5 joints with synovitis.  
Tenderness on physical examination was detected in 7 out of the 55 (12.7%) joints with bone erosions, 
in 5 (12.2%) individuals. In particular, joint tenderness was found in 6 out of 42 (14.3%) MTP5 joints, 
in 1 out of 10 (10%) MCP2 joints, and in none of the 3 MCP5 joints with bone erosions. Bone erosions 
were detected in combination with US synovitis in 3 out of the 7 (42.8%) joints which were tender on 
physical examination. The relationship between the US and x-ray findings is reported in 
Supplementary Table 1 and Supplementary Table 2.  
- The predictive value of the US bone erosions for the development of IA 
A total of 123/400 (30.7%) CCP+ at-risk individuals developed IA (median follow-up: 301 days, IQR 112-
721), 95 (77.2%) of whom fulfill the 2010 RA classification criteria. In particular, 25 out of the 41 
(61.0%) individuals with US bone erosions, and 98 out of 359 (27.3%) individuals without US bone 
erosions, developed IA (p<0.01).  
The odds ratios of the US findings for the development of IA are reported in Table 3. The results are 
adjusted for age, sex, smoking exposure, anti-CCP2 titre and RF status, except when the combination 
of the US and clinical findings was analyzed (i.e., presence of bone erosions + high titre anti-CCP2 Ab 
± RF). In this case, the analysis was not adjusted for anti-CCP2 titre and RF status as they were 
independent variables.  
Table 3. Predictive value of the US findings for the development of IA (ever, at 1 year, at 3 years) 
 Ever At 1 year At 3 years 
 OR (95%CI) 
P 
value 
OR (95%CI) 
P 
value 
OR (95%CI) P value 
Presence of bone erosion in д1 joint (any 
joint) 
4.0 
(1.8-8.7) 
<0.01 
3.6 
(1.7-7.5) 
<0.01 
3.5 
(1.6-7.4) 
<0.01 
- in the MCP2 joints 2.4 0.26 1.1 0.94 1.7 0.53 
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(0.5-11.1) (0.2-5.8) (0.4-7.0) 
- in the MCP5 joints 1.4 
(0.1-31.0) 
0.85 0 1 0 1 
- in the MTP5 joints 4.8 
(2.0-11.6) 
<0.01 
5.2 
(2.3-11.8) 
<0.01 
5.4 
(2.3-12.9) 
<0.01 
Presence of bone erosion and synovitis in 
the same joint (any joint) 
3.9 
(1.2-12.8) 
0.02 
6.0 
(2.1-17.5) 
<0.01 
3.9 
(1.3-11.8) 
0.02 
Presence of bone erosion and synovitis in 
the same MTP5 joint 
5.1 
(1.4-18.9) 
0.02 
7.0 
(2.3-21.7) 
<0.01 
4.9 
(1.5-16.2) 
<0.01 
Presence of bone erosion in >1 joint (any 
joint) 
10.6 
(1.9-60.4) 
<0.01 
5.7 
(1.7-19.5) 
<0.01 
7.3 
(1.7-31.7) 
<0.01 
Presence of bone erosion in д1 joint (any 
joint) + high titre anti-CCP2 Ab  
5.3 
(2.2-12.7) 
<0.01 
4.2 
(1.9-9.3) 
<0.01 
4.2 
(1.9-9.4) 
<0.01 
Presence of bone erosion in д1 joint (any 
joint) + high titre anti-CCP2 Ab and positive 
RF 
16.9 
(2.1-132.8) 
<0.01 
4.1 
(1.4-11.5) 
<0.01 
7.1 
(1.9-26.4) 
<0.01 
 
As shown in Table 4, the presence of bone erosion in the MTP5 joints was the most significant factor 
for the development of IA in the multivariable analysis. 
Table 4. Final multivariate logistic regression model for the development of IA at 1 year (A) and 3 years (B). 
 B 
Standard 
Error 
Wald df Sig. OR 95% CI of the OR 
       
Lower 
bound 
Upper 
bound 
A 
Presence of bone erosions in 
the MTP5 joints 
1.65 0.41 15.90 1 <0.01 5.2 2.3 11.7 
High titre anti-CCP2 Ab 0.87 0.42 4.31 1 0.04 2.4 1.1 5.4 
RF positivity 1.05 0.30 12.24 1 <0.01 2.9 1.6 5.2 
Smoking exposure (current or 
previous) 
0.70 0.34 4.2o 1 0.04 2.0 1.1 3.9 
Constant -3.08 0.39 60.92 1 <0.01 0.1   
Model summary. Nagelkerke R2: 0.21, Cox and Snell R2: 0.13 
 B 
Presence of bone erosions in 
the MTP5 joints 
1.70 0.44 14.88 1 <0.01 5.5 2.3 12.9 
High titre anti-CCP2 Ab 1.36 0.39 12.12 1 <0.01 3.9 1.8 8.3 
RF positivity 1.10 0.27 17.16 1 <0.01 3.0 1.8 5.1 
Smoking exposure (current or 
previous) 
0.71 0.35 4.18 1 0.04 2.0 1.0 4.0 
Constant -3.44 0.41 69.40 1 <0.01 0.0   
Model summary. Nagelkerke R2: 0.30, Cox and Snell R2: 0.21. 
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IﾐSｷ┗ｷS┌;ﾉゲ ┘ｷデｴ HﾗﾐW Wヴﾗゲｷﾗﾐゲ ｷﾐ дヱ ﾃﾗｷﾐデ (any joint) show a significantly reduced IA free survival rate 
compared to individuals without bone erosion (p<0.01) (Figure 1a). At 1 year follow-up, 31.7% of 
individuals with bone erosions ｷﾐ дヱ ﾃﾗｷﾐデ (any joint), and 61.5% of individuals with bone erosions in 
>1 joint (any joint) developed IA, compared to only 14.8% of individuals without bone erosions (p=0.04 
and p<0.01, respectively).  
The same trend was observed evaluating the US findings at MTP5 joints level (Figure 1b). At 1 year of 
follow-up, 36.6% of individual with bone erosions ｷﾐ дヱ MTP5 joints, but only 14.6% of subjects without 
bone erosions, developed IA (p=0.04). At the same time-point, the rate of progression to IA was 
significantly higher for the subjects showing bone erosion and synovitis in the MTP5 joints (68.8%) 
than the rate of progression of the individuals with bone erosions only (without synovitis) (p=0.03).  
At 1 year follow-up, the rate of progression to IA of individuals with high titre anti-CCP2 Ab (without 
bone erosion) was 14.8% (Figure 1c). Interestingly, this goes up to 40% in presence of bone erosions 
ｷﾐ дヱ ﾃﾗｷﾐデ ふ;ﾐ┞ ﾃﾗｷﾐデぶ ふヮаヰくヰヱぶが ;ﾐS デﾗ ヶヱくヱХ ｷﾐ I;ゲW ﾗa HﾗﾐW Wヴﾗゲｷﾗﾐゲ ｷﾐ дヱ ﾃﾗｷﾐデ ふ;ﾐ┞ ﾃﾗｷﾐデぶ ;ﾐS ヮﾗゲｷデｷ┗W 
RF (p<0.01). This last analysis was adjusted only for the following confounders: age, sex, smoking 
exposure and RF status.  
 
Discussion 
The results of our study suggest that an efficient, targeted US protocol, evaluating a set of only three 
joints (bilaterally), provides important information regarding the prevalence, distribution, and the 
predictive role of US bone erosions for the development of IA in CCP+ at-risk individuals. A focused US 
examination on the classical sites for RA damage (in particular the MTP5 joints) has the potential to 
improve risk-stratification and inform the management of CCP+ at-risk individuals. We demonstrated 
that US detected bone erosions in selected joints are useful to predict progression (and its timing) to 
IA in CCP+ at-risk individuals, with the risk of progression increasing with the number of joints with 
bone erosions, and with the presence of bone erosions in the MTP5 joints, especially when in 
combination with synovitis. Of note, around two-thirds of individuals with bone erosions in more than 
one joint (any joint), or with bone erosion and synovitis in the same MTP5 joint, progressed to IA 
within 12 months of observation. Therefore, the detection of such US findings appears particularly 
┌ゲWa┌ﾉ aﾗヴ デｴW ｷSWﾐデｷaｷI;デｷﾗﾐ ﾗa ｷﾐSｷ┗ｷS┌;ﾉゲ ;デ ｴｷｪｴ ヴｷゲﾆ ﾗa ｷﾏﾏｷﾐWﾐデ ;ヴデｴヴｷデｷゲ ふг ヱヲ ﾏﾗﾐデｴゲぶ; these 
individuals should be followed closely and potentially considered for preventive intervention (e.g. 
clinical trials), especially if presenting with high titre anti-CCP2 Ab and positive RF. 
The prevalence of bone erosions in the MTP5 joints was relatively high (7.4%), and significantly higher 
than the prevalence of bone erosions in the in the MCP2 joints (2.7%) and MCP5 joints (0.7%) (p<0.01). 
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Indeed, previous x-rays and US studies have revealed that the foot is one of the earliest sites of joint 
damage in patients with RA, with the MTP5 joints often representing the first site of bone erosions in 
those with early disease (26-28). Moreover, the MTP5 joints appear to be a very specific site for the 
identification of US bone erosion in patients with RA. In fact, in the above-mentioned study carried 
out by Zayat et al., bone erosions (of any size) in the MTP5 joints were highly specific for RA (21). 
Moreover, in a large study carried out on 207 healthy subjects, bone erosions were not detected in 
any of the MTP5 joints evaluated (29). The results of our study suggest that a careful examination of 
the feet is required in CCP+ at-risk individuals given the relatively high prevalence of bone erosions at 
this level. 
To the best of our knowledge, this is the first study evaluating the association between US bone 
erosions and synovitis (at joint level) in CCP+ at-risk individuals. We found a significant association 
between bone erosions and synovitis in the MTP5 joints (Cヴ;ﾏWヴげゲ VЭヰくンΑが ヮаヰくヰヱ). One explanation 
is that bone erosions may occur as a consequence of persistent, subclinical joint inflammation which, 
acting alongside site-specific mechanical stress, leads to structural joint damage (30, 31). On the other 
hand, joint damage could determine the release of bone and cartilage degradation elements. These 
act as possible triggers for local inflammation thereby initiating a vicious circle of inflammation and 
joint damage (32). However, this appears more likely to occur in patients with already established 
disease.  In the joints with bone erosions but no concomitant synovitis (60%), the presence of 
structural damage could be interpreted as the result of a previous inflammatory process that was not 
detected at the time of the US scan. Another very intriguing hypothesis links the development of bone 
damage to the direct effect of anti-citrullinated protein Ab (through the activation of osteoclasts), 
before the onset of clinical synovitis (5, 33). Interestingly, the OR for the progression to IA increased 
from 4.8 (2.0-11.6) to 5.1 (1.4-18.9), when bone erosions in the MTP5 joints were detected in 
combination with synovitis. 
Only a few joints showing bone erosions were tender on physical examination (12.7%), despite the 
identification of concomitant US synovitis in almost half of these joints. This is an interesting finding 
for which there might be different explanations. First, we could assume that the presence of low-grade 
subclinical inflammation might lead to structural damage (in the long term) without significant 
symptoms. Another explanation could be that the physical examination might be not sensitive (or not 
enough accurate) at foot level, especially in patients who do not complain of foot pain. Our results 
highlight the importance of using US for the evaluation of bone erosions (with or without synovitis) in 
the classic sites for RA damage in CCP+ at-risk individuals, with a particular focus on the MTP5 joints; 
clinical examination may often be falsely reassuring in these individuals.  
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Our study has the following limitations. First, the lack of other imaging tools, such as magnetic 
resonance imaging (MRI) or computed tomography (CT), to confirm the presence of bone erosions, 
especially when <2 mm. This may have been useful especially in light of the fact that bone erosions 
have been found in healthy subjects, both on US and MRI (34-36). However, particular attention in the 
assessment of cortical bone breaks of small size was paid by the sonographers to avoid 
misinterpretation of the US findings (i.e., anatomical necks or vascular bone channels).  Moreover, 
several studies have already demonstrated the good correlation between US, MRI and CT for the 
detection of bone erosions (37-39), thus suggesting that US is reliable and accurate for the assessment 
of structural damage in patients with RA. The US protocol used in our study did not clearly specify the 
site of bone erosions at wrist level (radio-carpal joint, ulno-carpal joint, inter-carpal joint, or distal 
ulna) and the distal ulna, which has also been described as a specific site for the detection of US bone 
erosions in patients with RA (21), was not included. Moreover, targeting the US evaluation only to the 
classic sites of RA damage could be considered another limitation of the study, as this might have led 
to underestimating the prevalence of bone erosions in CCP+ at-risk individuals.  
The prevention of RA has the potential to completely transform the clinical approach to this disease, 
and represents one of the most intriguing challenges in modern rheumatology (40). In this context, 
the identification of reliable and clinically available biomarkers of disease progression, which allow 
identification individuals at high risk of developing clinical disease, becomes extremely important. 
Conclusions 
The MTP5 joints appear to be an early site of erosive damage in individuals at-risk of RA without clinical 
synovitis. US bone erosions were mainly detected in asymptomatic joints, but frequently in association 
with subclinical synovitis. In CCP+ at-risk individuals, US bone erosions in >1 joint, and bone erosions 
in the MTP5 joints in combination with synovitis, are the most predictive for the development of 
clinical arthritis. Our results suggest that a focused US examination of the classical sites for RA damage, 
evaluating a set of only three joints (bilaterally), has the potential to improve risk-stratification and 
therefore inform management of CCP+ at-risk individuals. 
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